Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
Date:4/22/2009

Next Generation Pro-Healing Technology Developments Unveiled

SEOUL, South Korea, April 22 /PRNewswire/ -- OrbusNeich's pro-healing stent technology was featured at a symposium during Angioplasty Summit TCT Asia Pacific 2009 at the Convention Center of Sheraton Grande Walkerhill Hotel in Seoul, South Korea.

Presented by Margo Klomp, MD from the Academic Medical Center (AMC), Amsterdam, The Netherlands, final adjudicated 12 month follow up results from the randomized AMC single center TRIAS High Risk (HR) study showed a slightly higher target lesion revascularization (TLR) rate with the Genous treated patient group compared with patients receiving the Taxus drug eluting stent, but there were no stent thrombosis events at any time period in the 98 patient Genous group with only one month of dual antiplatelet therapy (DAPT). In the 95 patient Taxus cohort, the stent thrombosis rate was 4.2%, including late stent thromboses at 155 and 200 days, even though all patients were on DAPT at the time of stent thrombosis. Furthermore, the composite of death and myocardial infarction for Genous was 4.1% versus 7.3% for Taxus. "Within a month we will complete two year follow up on these patients and we anticipate these results will hold up longer term," said Klomp.

In a separate study involving 446 consecutive patients presented with an acute myocardial infarction (AMI) treated with Genous, Harry Suryapranata, MD, PhD, from Isala Klinieken in Zwolle, The Netherlands, presented 30 day follow up with only one patient (0.2%) having a stent thrombosis. Suryapranata commented, "This rate is impressively low given the highly thrombotic environment associated with AMI patients." Longer term follow up is ongoing.

Juan F Granada, MD, medical director of the Skirball Center for Cardiovascular Research at Columbia University Medical Center, presented results from pre-clinical models demonstrating the
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
3. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
4. VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
5. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
8. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
9. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
10. RVX-208 Data Demonstrates Increase in Functional HDL Particles
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...wire/ -- Spectrum Blue Steel is emerging as one of... planet. Through the efforts of True Green Energy ...ing Specialist Leroy Johnston, who has been in the... Spectrum Blue Steel is light years ahead of every...ngs because of the bi products recovered by using ...
(Date:12/2/2009)...wswire/ -- Nearly 600 medical research executives,...ened to explore novel development approaches and i...tnering for Cures meeting. ,, FasterCures, ...e, convened Partnering for Cures to facilitate m...ific discovery into an accessible therapy. This e...
(Date:12/2/2009)... , - "Bolstering Biodiver...,, Coinciding with the International Year o...c is hosting an international conference in Librev...al resources in Africa. The,conference will be att...scientific experts, private companies, representat...
(Date:12/2/2009)...e/ -- S*BIO Pte Ltd today announced data presentat...The American Society of Hematology 51st Annual Mee...l be presented on the clinical results from the Ph...s safety, tolerability and pharmacokinetic/pharmac...om 100 to 600 mg. These doses were administered on...
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...8 ,Neurobiological Technologies, Inc. (NTI(R)) (Na...il 1, 2008, Matthew M. Loar has been appointed Chi...e Company,s headquarters in,Emeryville. Mr. Loar j...ved,as Chief Financial Officer since 2006., "Matt...ficer, and we,will look to his expertise to help g...
...Solutions Holdings PLC,("Plethora", AIM: PLE), the...t and management of urological disorders, today an...t financing agreement with Paul Capital,Healthcare... to $28 million,in cash with $15 million payable u... commercial sale of PSD502 (PLE,s development stag...
... Rx,Corporation (OTC Bulletin Board: PMQC, PMQCU, ...cy services, announced today that it has postponed...lts and discuss 2008 outlook,that was originally s...onal,details about the timing of the 2007 financia...ce call will be forthcoming shortly., About Chem ...
Other Biology Technology:Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results 2
(Date:12/4/2009)...electroencephalogram (EEG) is widely used by physi...o diagnose neurological disorders. However, it has...n the head give an exact view of what is happening...stitute for Biological Cybernetics in Tbingen, Ger...tivity generated within the brain to that measured...
(Date:12/4/2009)...major discovery is challenging accepted thinking a...ated with diseases such as Alzheimer,s and Parkins...rapeutics. , It was believed that amyloid fibril...imes known as fibres - are inert, but that there m...n damage cells and cause disease. , But in a pa...
(Date:12/3/2009)...r ability to learn new information and adapt to ch...in lifelong memories, appears to lie in the minute...g to a new study by NYU Langone Medicine Center re... in the journal Nature . , The scientists, led...iology and neuroscience at NYU School of Medicine,...
Breaking Biology News(10 mins):How to read brain activity? 2New therapy targets for amyloid disease 2Lifelong memories linked to stable nerve connections 2Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 1Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 2Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 1Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 2Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 1Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 2
...dicine researchers have discovered how new neurons...o regions of the brain where they can replace old ...cell therapies can be specifically targeted to bra...or by stroke. , Associate Professor Qun-Yong Zhou ...ent of Pharmacology have identified a protein that...
...ton University in St. Louis has shown that for som...exual organs, and actually choose them for mating.... sex organ, called a gonopodium. These fish out-co... environment because they have a faster burst spee...ut because the size of their organ slows them down...
... world are breathing a sigh of relief, as they no ...atural disease-fighting substances. Scientists rec...emnii, which lives symbiotically inside the sea sq...compounds that may one day be used in cancer treat...uld not successfully cultivate Prochloron in the l...
Other Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Certain fish have a special mating preference 2Certain fish have a special mating preference 3Certain fish have a special mating preference 4
Stat-Pack Aldolase Controls from Caldon Biotech, Inc.
EDTA, 0.5 M solution from GE Healthcare, formerly Amersham Biosciences
Human VEGFR2 (KDR), phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Mouse sTNF RII / TNFRSF1B from R&D Systems
Biology Products: